Oral Solid Dosage Contract Manufacturing Market to Rise at CAGR of 4.4% to Reach US$ 40,776.0 Million by 2034: Fact.MR Study

The oral solid dosage contract manufacturing market is projected to reach a value of US$ 26.46 billion in 2024, and is anticipated to grow at a CAGR of 4.4% over the next decade, achieving US$ 40.78 billion by 2034.

This growth trajectory is fueled by the rising trend of pharmaceutical outsourcing, as drug manufacturers increasingly turn to Contract Manufacturing Organizations (CMOs) for cost-effective and scalable production solutions. Oral solid dosage forms-such as tablets and capsules-remain the most widely used drug delivery method due to their convenience, stability, and patient compliance.

As pharmaceutical companies continue to streamline operations and reduce in-house manufacturing burdens, CMOs with expertise in oral solid dosage production are well-positioned to capture greater market share and capitalize on evolving industry needs.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9634

Challenges to Success in Oral Solid Dosage Contract Manufacturing

Manufacturers specializing in oral solid dosage contract manufacturing encounter significant challenges stemming from stringent regulatory requirements and evolving compliance standards. Navigating these varied regulations often results in increased costs and production delays.

In the pharmaceutical industry, ensuring consistent product quality is paramount. Producers of oral solid dosage forms must adhere to rigorous quality control protocols to guarantee the safety and effectiveness of their products, which can extend production timelines and elevate expenses.

Another critical challenge lies in the risk of intellectual property disputes between clients and contract manufacturers. Establishing clear agreements and robust confidentiality measures is essential to safeguard proprietary formulations and manufacturing processes.

Country-wise Analysis

The oral solid dosage contract manufacturing market in North America is projected to grow at a CAGR of 4.1% through 2034. This growth is primarily driven by increasing demand in key countries such as the United States and Canada. The United States is expected to lead the market, capturing an estimated 92.5% share by 2034.

In East Asia, the oral solid dosage contract manufacturing market is set to expand at a robust CAGR of 10.3% through 2034. China stands out as the dominant player in this region, accounting for approximately 80.5% of the market share in East Asia by 2034.

Category-wise Outlook

By prescription type, the tablets segment is projected to hold the largest share of 59.9% by 2034. Meanwhile, the capsules segment is expected to secure a significant share of 33.8% by the same year, making substantial contributions to market growth.

Similarly, based on disintegration type, tablets dominate the market with a 59.9% share forecasted by 2034, followed by capsules with a 33.8% share.

Competitive Analysis

Key players in the oral solid dosage contract manufacturing market include Recipharm, Aenova Holding, Catalent, AbbVie, Patheon N.V. (Thermo Fisher Scientific), NextPharma, Capsugel (Lonza Group AG), Aurobindo Pharma Limited, Siegfried AG, Piramal Pharma Solutions, Corden Pharma, Kremoint Pharma Pvt Ltd., HERMES PHARMA GmbH, Medipaams India Private Limited, Alpex Pharma, Abaris Healthcare Pvt Ltd, Ardena Holdings N.V., Aphena Pharma Solutions, Actiza Pharmaceutical Private Limited, Sunwin Healthcare Pvt. Ltd., Saffron Medicare Pvt. Ltd., Kosher Pharmaceuticals, Dr. Reddy's Laboratories, GlaxoSmithKline Plc, and Boehringer Ingelheim BioXcellence.

The market is highly competitive, driven by growing demand for outsourced pharmaceutical manufacturing services. Leading contract manufacturing organizations (CMOs) compete vigorously by forming strategic partnerships, expanding their production capabilities, and adopting advanced technologies. Cost efficiency, scalability, and adherence to quality standards are key factors intensifying competition among these players.

Notable Advancements

In May 2022, Catalent, Inc. announced a US$175 million investment to expand its flagship large-scale oral dosage manufacturing facility in Winchester, Kentucky.
In June 2019, Piramal Pharma Solutions (PPS) inaugurated a new wing at its Riverview facility dedicated to producing High Potency Active Pharmaceutical Ingredients (HPAPIs) with Low Occupational Exposure Levels (OELs), enhancing its manufacturing capabilities in specialized pharmaceutical products.

Browse Full Report: https://www.factmr.com/report/oral-solid-dosage-contract-manufacturing-market

Segmentation of Market Research

By Prescription Type:
Tablets
Over-the-Counter
Prescription
Capsules
Over-the-Counter
Prescription
Powders and Granules (MT)
Over-the-Counter
Prescription
By Disintegration Type:
Tablets
Immediate Release
Modified Release
Chewable Tablets
Effervescent Tablets
Capsules
Controlled Release
Enteric Release
Others
Powders and Granules (MT)
Uncoated Powders and Granules
Coated Granules
By End User:
Big Pharma or Biotech Companies
Small and Medium Size Pharma or Biotech Companies
Emerging or Virtual Pharma Companies
Nutraceutical Companies
By Region:
North America
East Asia
East Asia
South Asia and Pacific
Western Europe
Eastern Europe
The Middle East and Africa

Check out More Related Studies Published by Fact.MR:

Asthma Spacers Market
https://www.factmr.com/report/4596/asthma-spacers-market
Back Table and Cart Covers Market
https://www.factmr.com/report/4357/back-table-and-cart-covers-market
Carbapenem-based Antibiotics Market
https://www.factmr.com/report/4425/carbapenem-based-antibiotics-market
Depression Drugs Market
https://www.factmr.com/report/3215/depression-drugs-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.